64019-93-8
中文名稱
鹽酸地匹福林
英文名稱
Dipivefrin hydrochloride
CAS
64019-93-8
分子式
C19H30ClNO5
分子量
387.898
MOL 文件
64019-93-8.mol
更新日期
2024/03/22 17:31:02
64019-93-8 結(jié)構(gòu)式
基本信息
中文別名
鹽酸地匹福林鹽酸二維弗林
鹽酸地哌夫林
5-羥基色氨酸對(duì)照品
鹽酸地匹福林 EP標(biāo)準(zhǔn)品
鹽酸地匹福林 [64019-93-8]
4-(1-羥基-2-(甲基氨基)乙基)-1,2-苯二醇二特戊酸酯鹽酸鹽
英文別名
ProgateDiopine
Pivalephrine
Dipivefrine HCL
hydrochloride,(+-)-este
dipivefrinhydrochloride
dipivefrinehydrochloride
Dipivefrine hydrochloride CRS
dipivalylepinephrinehydrochloride
DIPIVEFRIN HYDROCHLORIDE (200 MG)
所屬類別
原料藥：眼科用藥物理化學(xué)性質(zhì)
熔點(diǎn)158-159°
儲(chǔ)存條件Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解度Freely soluble in water, very soluble in methanol, freely soluble in ethanol (96 per cent) and in methylene chloride.
酸度系數(shù)(pKa)8.40(at 25℃)
形態(tài)neat
顏色白色至灰白色
主要應(yīng)用pharmaceutical (small molecule)
InChIInChI=1S/C19H29NO5.ClH/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6;/h8-10,13,20-21H,11H2,1-7H3;1H
InChIKeyVKFAUCPBMAGVRG-UHFFFAOYSA-N
SMILESC1(OC(=O)C(C)(C)C)=CC(=CC=C1OC(=O)C(C)(C)C)C(O)CNC.Cl
安全數(shù)據(jù)
警示詞危險(xiǎn)
危險(xiǎn)性描述H301
防范說(shuō)明P264-P270-P301+P310+P330-P405-P501
危險(xiǎn)品運(yùn)輸編號(hào)UN 2811 6.1 / PGIII
WGK GermanyWGK 3
海關(guān)編碼2922504500
存儲(chǔ)類別6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects
toxic compounds or compounds which causing chronic effects
危險(xiǎn)性類別Acute Tox. 3 Oral
鹽酸地匹福林價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/12/22 | HY-B1323 | 鹽酸地匹福林 Dipivefrin hydrochloride | 64019-93-8 | 5 mg | 191元 |
| 2025/12/22 | HY-B1323 | 鹽酸地匹福林 Dipivefrin hydrochloride | 64019-93-8 | 10mg | 310元 |
| 2025/12/22 | HY-B1323 | 鹽酸地匹福林 Dipivefrin hydrochloride | 64019-93-8 | 25mg | 621元 |
常見問題列表
生物活性
Dipivefrin hydrochloride (Dipivefrine hydrochloride) 是一種抗青光眼前體藥物，通過角膜中的酯酶水解為其活性化合物腎上腺素。體內(nèi)研究
Dipivefrin hydrochloride (0.3-10 μg/kg; i.p.;) induces enhancement of memory involves central beta- but not alpha-adrenergic mechanisms.
| Animal Model: | Male 60-day-old CFW mice (23-28 g) |
| Dosage: | 0.3 μg/kg, 1.0 μg/kg, 3.0 μg/kg, 10 μg/kg |
| Administration: | Intraperitoneal injection; post-training |
| Result: | Significantly enhanced retention of both inhibitory avoidance and Y-maze discrimination tasks in a dose-dependent manner. |